Microbix Biosystems Inc. (MBX.TO)
Toronto · CAD · Healthcare · Biotechnology
CA$0.305 (-3.17%) as of
Key statistics
- Market cap
- 41.78M
- Forward P/E
- 15.25
- EPS (TTM)
- -0.0400
- Dividend yield
- 0.00%
- 52-week range
- 0.2100 – 0.3300
- Beta
- 0.54
- Revenue (TTM)
- 15.4M
- Profit margin
- -31.72%
- Analyst target
- CA$0.40
- Volume
- 6.00k
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Mississauga, ON, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.